{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:15:10Z","timestamp":1789884910056,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Ticagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso\u2010occlusion crisis (\n                    <jats:styled-content style=\"fixed-case\">VOC<\/jats:styled-content>\n                    ) in sickle cell disease (\n                    <jats:styled-content style=\"fixed-case\">SCD<\/jats:styled-content>\n                    ). The\n                    <jats:styled-content style=\"fixed-case\">HESTIA<\/jats:styled-content>\n                    2 study (\n                    <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n                    02482298) randomised 87 adults with\n                    <jats:styled-content style=\"fixed-case\">SCD<\/jats:styled-content>\n                    (aged 18\u201330\u00a0years) 1:1:1 to twice\u2010daily ticagrelor 10, 45\u00a0mg or placebo for 12\u00a0weeks. Numerical decreases from baseline in mean proportion of days with patient\u2010reported pain (primary endpoint) were seen in all three groups, as well as in pain intensity and analgesic use, with no significant differences between placebo and ticagrelor treatment groups. Plasma ticagrelor concentrations and platelet inhibition increased with dose. Adverse events were distributed evenly across groups and two non\u2010major bleeding events occurred per group. Ticagrelor was well tolerated with a low bleeding risk, but no effect on diary\u2010reported pain was detected. Potential effects on frequency of\n                    <jats:styled-content style=\"fixed-case\">VOC<\/jats:styled-content>\n                    s will need to be evaluated in a larger and longer study.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15646","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T04:51:44Z","timestamp":1542343904000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ticagrelor does not impact patient\u2010reported pain in young adults with sickle cell disease: a multicentre, randomised phase\n                    <scp>II<\/scp>\n                    b study"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-8891","authenticated-orcid":false,"given":"Julie","family":"Kanter","sequence":"first","affiliation":[{"name":"Medical University of South Carolina Charleston SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel R.","family":"Abboud","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Centre Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Kaya","sequence":"additional","affiliation":[{"name":"Royal London Hospital Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Videlis","family":"Nduba","sequence":"additional","affiliation":[{"name":"Kenya Medical Research Institute Centre for Respiratory Diseases Research Nairobi Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Amilon","sequence":"additional","affiliation":[{"name":"Quantitative Clinical Pharmacology Early Clinical Development IMED Biotech Unit Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Gottfridsson","sequence":"additional","affiliation":[{"name":"Patient Safety Centre of Excellence CV Global Medicines Development AstraZeneca R&amp;D Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rensfeldt","sequence":"additional","affiliation":[{"name":"Global Medicines Development AstraZeneca R&amp;D Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leonsson\u2010Zachrisson","sequence":"additional","affiliation":[{"name":"Global Medicines Development AstraZeneca R&amp;D Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HESTIA2 study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248413511693"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029786"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03669.x"},{"key":"e_1_2_8_7_1","first-page":"199","article-title":"Clinical and biological double\u2010blind\u2010study of ticlopidine in preventive treatment of sickle\u2010cell disease crises","volume":"15","author":"Cabannes R.","year":"1984","journal-title":"Agents and Actions. Supplements"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21905"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079923"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.912550"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512021"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-09-0731"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000220374.00602.a2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.08.003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1955"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04433.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.12.016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23181"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.06.018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-2-200801150-00004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0290-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-17"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15646","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:58:46Z","timestamp":1694379526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15646"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15646","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734452666.793575211","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"2018-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}